An analysis of the slowdown in growth of spending for psychiatric drugs, 1986-2008

Psychiatric Services

Volumn 63, Issue 1, 2012, Pages 13-18

  Mark, Tami L ^a   Kassed, Cheryl ^a,b   Levit, Katharine ^a   Vandivort Warren, Rita ^c  

^a THOMSON REUTERS   (United Kingdom)

^b Health Analytics in Columbia   (United States)

^c SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; GENERIC DRUG; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; DRUG COST; DRUG SAFETY; DRUG UTILIZATION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; PRESCRIPTION; PSYCHIATRIC TREATMENT; TREND STUDY;

DRUG COSTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUGS, GENERIC; HEALTH CARE SURVEYS; HEALTH EXPENDITURES; HUMANS; MENTAL DISORDERS; PRESCRIPTION DRUGS; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 84857875237     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201100564     Document Type: Article

References (32)

1. Mark T, Levit K, Coffey R, et al: National Expenditures for Mental Health Services and Substance Abuse Treatment, 1993-2003. DHHS pub no SMA 07-4227. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2007
2. Mark T, Coffey R: What drove private health insurance spending on mental health and substance abuse care, 1992-1999? Health Affairs 22(1):165-172, 2003 (Pubitemid 41388772)
3. Zuvekas SH: Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Affairs 24 (1):195-205, 2005
4. Frank RG, Goldman HH, McGuire TG: Trends in mental health cost growth: an expanded role for management? Health Affairs 28:649-659, 2009
5. Mark TL, Stranges ES, Levit KR, et al: National Expenditures for Mental Health Services and Substance Abuse Treatment, 1986-2005. DHHS pub no SMA 10-4612. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2010
6. Mark TL, Levit KR, Vandivort-Warren R, et al: Changes in US spending on mental health and substance abuse treatment, 1986-2005, and implications for policy. Health Affairs 30:284-292, 2011
7. Hansen J, Chang S: Health Research Data for the Real World: The Thomson Reuters MarketScan Databases. Washington, DC, Thomson Reuters, 2010. Available at www.marketscan.thomsonreuters.com/marketscanuniversity/publications.aspx. Accessed Sept 13, 2010
8. Mark TL: For what diagnoses are psychotropic medications being prescribed? A nationally representative survey of physicians. CNS Drugs 24:319-326, 2010
9. Facts and Myths About Generic Drugs. Silver Spring, Md, US Food and Drug Administration, 2009. Available at www.fda.gov
10. Employer Health Benefits 2010 Annual Survey. Menlo Park, Calif, and Chicago, Kaiser Family Foundation and Health Research and Educational Trust, 2010. Available at www.ehbs.kff.org/pdf/2010/8085.pdf
11. Hodgkin D, Parks Thomas C, Simoni-Wastila L, et al: The effect of a three-tier formulary on antidepressant utilization and expenditures. Journal of Mental Health Policy and Economics 11:67-77, 2008 (Pubitemid 351890748)
12. Gibson TB, Ozminkowski RJ, Goetzel RZ: The effects of prescription drug cost sharing: a review of the evidence. American Journal of Managed Care 11:730-740, 2005 (Pubitemid 41608213)
13. Busch SH, Frank RG, Leslie DL, et al: Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? Psychiatric Services 61:11-16, 2010
14. US Food and Drug Administration: Warning about hyperglycemia and atypical antipsychotic drugs. FDA Patient Safety News, June 2004. Available at www.accessdata.fda.gov
15. US Food and Drug Administration: Alert on atypical antipsychotics. FDA Patient Safety News, 2005. Available at www.accessdata.fda.gov
16. Ballard C, Hanney ML, Theodoulou M, et al: The Dementia Antipsychotic Withdrawal Trial (DART-AD): long-term follow-up of a randomized placebo-controlled trial. Lancet Neurology 8:151-157, 2009
17. Herper M: Lilly ferociously defends its top seller. Forbes.com, Sep 9, 2004. Available at www.forbes.com
18. Salzman C, Jeste DV, Meyer RE, et al: Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. Journal of Clinical Psychiatry 69: 889-898, 2008 (Pubitemid 351944940)
19. Dorsey ER, Rabbani A, Gallagher SA, et al: Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine 170:96-103, 2010
20. Pear R: Rising costs prompt states to reduce Medicaid further. New York Times, Sep 23, 2003
21. Mark TL, Gibson TM, McGuigan K, et al: The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures. American Journal of Psychiatry 167:1202-1209, 2010
22. Huskamp HA, Deverka PA, Epstein AM, et al: Impact of 3-tier formularies on drug treatment of attention-deficit hyperactivity disorder in children. Archives of General Psychiatry 62:435-441, 2005 (Pubitemid 40471693)
23. Zeber JE, Grazier KL, Valenstein M, et al: Effect of a medication copayment increase in veterans with schizophrenia. American Journal of Managed Care 13:335-346, 2007 (Pubitemid 46983130)
24. West JC, Wilk JE, Rae DS, et al: Medicaid prescription drug policies and medication access and continuity: findings from ten states. Psychiatric Services 60:601-610, 2009
25. Adams AS, Zhang F, LeCates RF, et al: Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Archives of Internal Medicine 169:750-756, 2009
26. Zhang Y, Adams AS, Ross-Degnan D, et al: Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatric Services 60:520-527, 2009
27. Lu CY, Soumerai SB, Ross-Degnan D, et al: Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Medical Care 48:4-9, 2010
28. Cook A: How Increased Competition From Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry. Washington, DC, Congressional Budget Office, 1998
29. Generic Pharmaceuticals. Paris, Organization for Economic Policy and Development, Policy Roundtable, Oct, 2009
30. Panattoni LE: The effect of paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. Journal of Health Economics 30:126-145, 2011
31. Insel TR: Who will develop the next generation of medications for mental illness? NIMH Director's Blog, Mar 30, 2010
32. Chang T, Fava M: The future of psychopharmacology of depression. Journal of Clinical Psychiatry 71:971-975, 2010